AC-262271
We have discovered and, in collaboration with Allergan, are developing AC-262271, a small molecule product candidate for the treatment of glaucoma. Glaucoma is a chronic eye disease and is the second leading cause of blindness in the world. Loss of vision is caused by degeneration of the optic nerve, which is responsible for carrying images from the eye to the brain. A frequent symptom of glaucoma is increased fluid pressure within the eye, referred to as intraocular pressure. In the early stages of the disease, there may be no symptoms. It is estimated that over 4 million people in the United States have glaucoma but only half of those know they have it. Older people are at a higher risk for glaucoma and the incidence of glaucoma is expected to increase as the average age of the population increases.
Using our proprietary discovery platform, we identified a subtype of the muscarinic receptors that controls intraocular pressure and discovered compounds that selectively activate this target. In preclinical models, AC-262271 has demonstrated a promising preclinical profile including robust efficacy and a long duration of action. Allergan is conducting Phase I development with AC-262271.
back to top